Lipocine Inc
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation lon… Read more
Lipocine Inc (LPCN) - Total Liabilities
Latest total liabilities as of September 2025: $1.93 Million USD
Based on the latest financial reports, Lipocine Inc (LPCN) has total liabilities worth $1.93 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lipocine Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how Lipocine Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Lipocine Inc Competitors by Total Liabilities
The table below lists competitors of Lipocine Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Element 29 Resources Inc
OTCQB:EMTRF
|
USA | $251.45K |
|
Empress Royalty Corp
OTCQB:EMPYF
|
USA | $6.09 Million |
|
Atenor SA
BR:ATEB
|
Belgium | €662.52 Million |
|
Unictron Technologies Corp
TW:6792
|
Taiwan | NT$447.84 Million |
|
Hyundai E P
KO:089470
|
Korea | ₩317.54 Billion |
|
Youlife Group Inc. American Depositary Shares
NASDAQ:YOUL
|
USA | $1.45 Billion |
|
Prodia Widyahusada Tbk PT
JK:PRDA
|
Indonesia | Rp261.44 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Lipocine Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lipocine Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lipocine Inc (2011–2024)
The table below shows the annual total liabilities of Lipocine Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.51 Million | -42.51% |
| 2023-12-31 | $2.63 Million | +37.93% |
| 2022-12-31 | $1.91 Million | -72.40% |
| 2021-12-31 | $6.91 Million | -30.95% |
| 2020-12-31 | $10.01 Million | -25.13% |
| 2019-12-31 | $13.37 Million | +17.10% |
| 2018-12-31 | $11.42 Million | +79.95% |
| 2017-12-31 | $6.35 Million | +378.46% |
| 2016-12-31 | $1.33 Million | -60.90% |
| 2015-12-31 | $3.39 Million | +107.64% |
| 2014-12-31 | $1.63 Million | +27.24% |
| 2013-12-31 | $1.28 Million | +10694.37% |
| 2012-12-31 | $11.89K | +56.38% |
| 2011-12-31 | $7.61K | -- |